

Special Issue

Vaccines and Immunization: Measles, Mumps, and Rubella

Message from the Guest Editor

Measles, mumps, and rubella are viral diseases with many complications. Measles can become severe and often lead to death, mumps are associated with hearing loss, and rubella infection in pregnant women can cause fetal infection and CRS at high rates. Fortunately, the number of cases has dropped dramatically in countries and regions where vaccines are widely used. However, the COVID-19 pandemic, poverty, and conflicts have significantly impacted vaccination efforts. In areas where immunization rates have declined, a resurgence of these diseases is also affecting neighboring countries. Moreover, while measles, mumps, and rubella have typically been viewed as childhood diseases, recent epidemiological trends show that their impact extends to adults and the elderly. This Special Issue aims to explore the future of these diseases, focusing on advancements in understanding their pathology and virology, changes in the epidemiological landscape, and progress in developing future vaccines. We look forward to your contributions and insights on this important topic.

Guest Editor

Dr. Nobuhiko Okabe

Kawasaki City Institute for Public Health, Kawasaki City 210-0821,
Kanagawa, Japan

Deadline for manuscript submissions

31 March 2027



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/237100

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).